Champions Oncology (Champions Oncology) Debt-to-Asset : 0.29 (As of Jan. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Debt-to-Asset?

Champions Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $1.31 Mil. Champions Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $6.44 Mil. Champions Oncology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was $26.79 Mil. Champions Oncology's debt to asset for the quarter that ended in Jan. 2024 was 0.29.

Champions Oncology Debt-to-Asset Historical Data

The historical data trend for Champions Oncology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Debt-to-Asset Chart

Champions Oncology Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Debt-to-Asset

Get a 7-Day Free Trial

0.18

0.35

0.27

0.25

Champions Oncology Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															0.25	0.25	0.28	0.29	0.29

Competitive Comparison of Champions Oncology's Debt-to-Asset

For the Biotechnology subindustry, Champions Oncology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Debt-to-Asset falls into.

Champions Oncology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Champions Oncology's Debt-to-Asset for the fiscal year that ended in Apr. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.208	+	7.391)	/	34.311
	=	0.25

Champions Oncology's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.305	+	6.437)	/	26.787
	=	0.29

Champions Oncology (NAS:CSBR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Champions Oncology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology (Champions Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

2I3:Germany

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

Executives

Daniel Newman Mendelson	director	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris	director, officer: President	855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld	director	ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp.	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman	director, officer: Chief Executive Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins	10 percent owner
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093